The Sleepless Brain: Neuroimaging Support for a Differential Diagnosis of Insomnia (SOMNET)

August 22, 2017 updated by: University Hospital, Bordeaux

One-tenth of the population suffers from insomnia, increasing their risk on other health problems such as depression. Self-reported sleep quality only was historically leading for insomnia diagnosis, but more recently a state of 24-hour hyperarousal has been associated with insomnia, either physiological (increased heart rate, higher frequency EEG) or predominant cognitive-emotional hyperarousal (worry, rumination, repetitive thoughts). Strong evidence shows that those suffering from insomnia with physiological hyperarousal are at higher risk of short and long term severe health problems such as inflammation and hypertension than the group without physiological hyperarousal. The neurophysiological basis of these insomnia phenotypes has however barely been investigated, although its results can have major consequences for how this limiting condition will be treated.

To support the development of a differential diagnosis of insomnia, structural and functional brain connectivity in insomnia patients with different levels of hyperarousal will be investigated and related to sleep variables. Investigators will compare the insomnia group to a normal sleeping control group. Investigators expect that the emotion processing circuit (amygdala-ventromedial prefrontal cortex) is a) more affected in insomniacs compared to normal sleeping controls and b) the directionality of this effect to depend on the level and type of hyperarousal in insomniacs. Further, investigators expect c) amygdala activity to be positive correlated with physiological hyperarousal level and d) prefrontal activity to be positively correlated with cognitive-emotional hyperarousal level. Investigators expect a higher physiological hyperarousal level to be reflected in affected afferent pathways of the amygdala towards the ventromedial prefrontal cortex and investigators expect higher cognitive-emotional hyperarousal to be related to affected efferent pathways from the ventromedial prefrontal cortex to the amygdala. Investigators expect sleep quality to play a mediating role in both types of hyperarousal and their brain activation patterns in insomnia patients and normal sleeping controls.

These data can lead to the definition of new insomnia phenotypes and to new customized and effective insomnia treatment, focused not only on improving sleep but also on changing dysfunctional hyperarousal levels that currently put insomniacs at risk of numerous severe health problems.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bordeaux, France, 33000
        • CHU de Bordeaux

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 50 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Insomnia group: patients with insomnia: sleep complaints, of at least 3 nights a week, for at least 3 months, affected daytime functioning.
  • control group: no self-reported sleep problems in the last 2 months.
  • 20-50 years old.
  • Male or female.
  • having given written informed consent to participate in the research project.

Exclusion Criteria:

  • Night and shift-workers.
  • Psychiatric disorder: clinical mood disorder, anxiety disorder, psychosis, bipolar disorder.
  • For insomnia group: all sleep disorders other than persistent insomnia.
  • For control group: all sleep disorders.
  • Progressive neurological diseases that include restless legs syndrome.
  • Cardiovascular disease other than treated hypertension.
  • Unstable respiratory or endocrinological diseases.
  • Drug addiction, alcohol addiction during the previous 6 months.
  • Having undertaken trans-meridian travel (± 3H) in the previous 1 month.
  • Pregnant or lactating women.
  • Chronic pain.
  • Hypnotic and psychotropic medication taking or stopped less than 5 half-life periods of molecules before screening V0.
  • Patient participating to any other interventional study.
  • For MRI: presence of a ferromagnetic foreign body (in particular certain intracranial clips, certain cardiac valves, intraocular foreign body, or subject having worked with metals), the presence of an implanted pacemaker, subject with cardiac or brain valves of ventricular derivation (risk of maladjustment), claustrophobia.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: BASIC_SCIENCE
  • Allocation: NON_RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Insomnia group
Patients with insomnia: sleep complaints, of at least 3 nights a week, for at least 3 months, affected daytime functioning, objectified low sleep quality (SE <85%) with 10 days actigraphy occurred in the last 2 months
EXPERIMENTAL: Control group
Volunteer without sleep problems either self-reported or objectified through actigraphy (SE ≥85%)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Resting state intrinsic connectivity within the emotion processing network by MRI
Time Frame: During Visit V2 (study termination), up to 3 month after consent signature
During Visit V2 (study termination), up to 3 month after consent signature

Secondary Outcome Measures

Outcome Measure
Time Frame
Total sleep time obtained by actimetry
Time Frame: During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Sleep efficiency obtained by actimetry
Time Frame: During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Wake after sleep onset obtained by actimetry
Time Frame: During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Sleep latency obtained by actimetry
Time Frame: During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Total sleep time obtained by sleep diary
Time Frame: During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Sleep efficiency obtained by sleep diary
Time Frame: During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Wake after sleep onset obtained by sleep diary
Time Frame: During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
sleep latency obtained by sleep diary
Time Frame: During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
During the 10 nights preceding Inclusion Visit (up to 1 month after consent signature)
Questionnaire regarding sleep problems : Pittsburgh Sleep Questionaire (PSQ)
Time Frame: During Pre-inclusion Visit, at consent signature
During Pre-inclusion Visit, at consent signature
Questionnaire regarding sleep problems : Insomnia Severity Index (ISI)
Time Frame: During Pre-inclusion Visit, at consent signature
During Pre-inclusion Visit, at consent signature
Questionnaire regarding depression : Beck Depression Inventory (BDI)
Time Frame: During Pre-inclusion Visit, at consent signature
During Pre-inclusion Visit, at consent signature
Questionnaire regarding anxiety : Beck Anxiety Inventory (BAI)
Time Frame: During Pre-inclusion Visit, at consent signature
During Pre-inclusion Visit, at consent signature
Questionnaire regarding arousal : Arousal Predisposition Scale (APS)
Time Frame: During Inclusion Visit, up to 1 month after consent signature
During Inclusion Visit, up to 1 month after consent signature
Questionnaire regarding sleep reactivity : Ford Insomnia Response to Stress Test (FIRST)
Time Frame: During Inclusion Visit, up to 1 month after consent signature
During Inclusion Visit, up to 1 month after consent signature
Questionnaire regarding presleep arousal state : Presleep State Arousal Scale (PSAS)
Time Frame: During Visit V2 (study termination), up to 3 month after consent signature
During Visit V2 (study termination), up to 3 month after consent signature
Questionaire regarding emotional state : Positive and Negative Affect Schedule (PANAS)
Time Frame: During Visit V2 (study termination), up to 3 month after consent signature
During Visit V2 (study termination), up to 3 month after consent signature

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

September 1, 2016

Primary Completion (ACTUAL)

April 3, 2017

Study Completion (ACTUAL)

April 3, 2017

Study Registration Dates

First Submitted

June 17, 2016

First Submitted That Met QC Criteria

June 28, 2016

First Posted (ESTIMATE)

July 1, 2016

Study Record Updates

Last Update Posted (ACTUAL)

August 23, 2017

Last Update Submitted That Met QC Criteria

August 22, 2017

Last Verified

August 1, 2017

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Insomnia

Clinical Trials on MRI

3
Subscribe